Skip to content
Open access

Neoadjuvant endocrine therapy in breast cancer: a single-institution epidemiological and clinicopathological analysis from southern Brazil

2026 · Mastology · 0 citations

Abstract

Introduction: Breast cancer accounts for approximately 11.6% of all oncologic diagnoses, with hormone receptor-positive (HR+) and HER2 negative (HER2-) tumors representing a significant proportion of cases. In this context, neoadjuvant endocrine therapy has emerged as a therapeutic alternative, with potential benefits in tumor downstaging and increased rates of breast-conserving surgery. The aim of this study was to describe the epidemiological and clinicopathological profile of patients with HR+/HER2− breast cancer undergoing neoadjuvant endocrine therapy in a public healthcare setting, as well as to analyze treatment response rates. Methods: An observational, analytical, retrospective study was conducted including patients treated between January 2019 and October 2025 who underwent surgery after neoadjuvant therapy. Clinical, pathological, and outcome variables were assessed. Results: The cohort included 25 patients, with a mean age of 73.7 years and multiple comorbidities. There was a predominance of T2 tumors (64%), N0 disease (60%), and histological grade 2 (68%), with high expression of hormone receptors (mean ER 92.6% and median PR 60%) and a median Ki-67 of 15%. Anastrozole was used in 96% of cases, with a median treatment duration of 8 months. The breast-conserving surgery rate was 64%, with a reduction in mean tumor size from 3.2 cm to 2.7 cm. The PEPI score was calculated in eligible patients, with scores greater than 4 in 68% of cases, and 12% presenting high residual axillary burden (ypN3a). At a median follow-up of 27 months, no locoregional recurrences were observed. Conclusion: In a real-world setting, neoadjuvant endocrine therapy proved to be safe and feasible for the treatment of HR+/HER2− breast cancer, particularly regarding tumor control and treatment timing. Proper patient selection may optimize surgical outcomes and support individualized treatment strategies.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.